research Ritlecitinib in severe alopecia areata: a profile of its use
Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
Search
for
Sort by
Research
780-810 / 1000+ results 
research Baseline methotrexate does not impact the incidence of infliximab infusion reactions: Results from a Canadian real-world treatment registry
Clofazimine effectively treated ashy dermatosis in a patient.
research Reversal of Alopecia Universalis by Tofacitinib: A Case Report
Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.
research Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopecia Areata: A Single-centre Real-world Retrospective Study
Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.
research Therapeutic response of facial papules and inflammation in frontal fibrosing alopecia to low-dose oral isotretinoin
Low-dose oral isotretinoin improved hair loss and facial bumps in patients with a specific type of hair loss.
research Ritlecitinib: First Approval
Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
research Functional Interpretation of Genome-Wide Association Study Evidence in Alopecia Areata
Alopecia areata is linked to immune-related genes, suggesting JAK inhibitors as a potential treatment.
![Discovery of 7-Methoxy-6-[4-(4-Methyl-1,3-Thiazol-2-yl)-1H-Imidazol-5-yl]-1,3-Benzothiazole (TASP0382088): A Potent and Selective Transforming Growth Factor-β Type I Receptor Inhibitor as a Topical Drug for Alopecia](/images/research/9620bd26-3366-4f2a-bcac-f511697bbc41/small/35997.jpg)
research Discovery of 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): A Potent and Selective Transforming Growth Factor-β Type I Receptor Inhibitor as a Topical Drug for Alopecia
A new compound shows promise as a topical treatment for hair loss.
research Current options and treatment strategies for alopecia ateata in comorbidity with atopic diseases
Dupilumab and oral JAK inhibitors are effective for treating alopecia areata with atopic diseases.
research Tofacitinib in alopecia areata and HIV: A curious intersection of immunomodulation, hair regrowth, and hypertrichosis
Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.
research Comparing the efficacy of oral apremilast, intralesional corticosteroids, and their combination in patients with patchy alopecia areata: a randomized clinical controlled trial
research Dupilumab treatment for atopic dermatitis leading to unexpected treatment for alopecia universalis
A medication for skin rash also unexpectedly treated hair loss in a patient.
research Tofacitinib in the Management of Alopecia Universalis
Tofacitinib helped a woman regrow hair with no major side effects.
research Data from Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
research P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
research The efficacy and safety of tofacitinib in patients with alopecia totalis
Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
research 710 Use of mass spectrometry imaging and a full thickness 3D skin equivalent for evaluation of percutaneous absorption
The document concludes that various topical treatments show promise for skin conditions like atopic dermatitis, psoriasis, and hair loss.
research Episodic Neuropathic-Like Musculoskeletal Pain Associated With Ritlecitinib Therapy in Alopecia Universalis: A Case Report
Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.
research Beyond Hair Regrowth: Interpreting the Psychosocial Impact of Ritlecitinib in Alopecia Areata
Ritlecitinib helps hair regrowth and reduces emotional and functional burdens in alopecia areata.
research In Silico Structure-Based Drug Design Approach To Evaluate Quercetin And Kaempferol As Dual Inhibitors Of Jak3 Kinase And 5-Alpha Reductase Type II with ADMET Profiling
This study explores the potential of quercetin and kaempferol, two plant-derived flavonoids, as dual inhibitors of JAK3 kinase and 5-alpha reductase type 2 (5-AR2) for treating androgenetic alopecia (AGA). Using molecular docking simulations, quercetin showed the strongest binding affinity to JAK3 kinase, surpassing the standard drug tofacitinib, while both flavonoids demonstrated moderate binding to 5-AR2, within the inhibitory range for polyphenolic flavonoids. Quercetin's favorable ADMET profile, including suitable skin permeability and safety, highlights its promise for topical application. These findings support further research into these compounds as safer, natural alternatives for AGA management.
research Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study
Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
research Consensus Document on the Clinical Management of Alopecia Areata: Recommendations from the Spanish Hair Research Group of the Spanish Academy of Dermatology and Venerology)
JAK inhibitors are recommended for severe alopecia areata if corticosteroids fail.
research Severe Pustular Drug Eruptions From Amivantamab: A Case Series
Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.
research Supplementary Material for: Drug-Induced Melasma in Patients on 5-Alpha Reductase Inhibitors: A Case Report
Finasteride can cause melasma, especially in people with darker skin.
research P44 The presentation of systemic erythematous lupus with Kikuchi-Fujimoto disease
A woman with lupus and Kikuchi-Fujimoto disease improved with treatment.
research Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature
Apremilast shows promise for several skin conditions but needs more research.
research Efficacy of Isotretinoin and Acitretin in Treatment of Frontal Fibrosing Alopecia: Retrospective Analysis of 54 Cases.
Isotretinoin and acitretin may effectively stabilize the hairline in patients with frontal fibrosing alopecia.
research Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib—A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata
A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
research An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa
Etanercept is safe and may help improve hidradenitis suppurativa, but more research is needed.
research Cemiplimab-Induced Alopecia Areata
A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.